Insights A checkpoint for antibody SPC applications in France?The French Supreme Court offers a new take on the interpretation of Article 3(a), as applied to an SPC application for an antibody that acts as an immune checkpoint inhibitorRead More 01Sep2025 No SPCs for new medical indications: Court of Appeal holds the “bright line”Merck Serono’s appeal dismissed by the Court of AppealRead More 29Aug2025 CJEU confirms guidance on Articles 3(a) and 3(c) in C-119/22 and C-149/22 MerckSPC applicants still facing uncertainty on Article 3(a)Read More 28Aug2025 AI and nuclear power: a self-sustaining cycle of patentable innovationAI is driving advances in nuclear technology, and nuclear is powering the AI revolution – together they are sparking a chain reaction of patentable inventionsRead More 13Aug2025 Future of AI patentability discussed at UK’s highest courtThe Supreme Court hearing in Emotional Perception AI v Comptroller-General has now concludedRead More 23Jul2025 Council adopts position on EU pharma packageMajor changes to the EU’s pharmaceutical regime, including to regulatory exclusivity periods, are now one step closer.Read More 03Jul2025 G 1/24: Description should be consulted for claim interpretation at the EPOClear guidance from the Enlarged Board of Appeal of the EPO (EBA) takes into account the approach of the UPC and could be a sign of increased harmonisation across Europe being catalysed by the new courtRead More 27Jun2025 How has the UPC responded to BSH v Electrolux over the last three months?Patent litigation forums around the world have been abuzz with discussions about the cross-border implications of the CJEU’s ruling in BSH v Electrolux (Case C-339/22) – summarised and further discussed here.Read More 24Jun2025 Meril v Edwards: First (Inventive) Steps Toward Harmonization of Obviousness at the UPC and the EPOA recent decision from the Munich Local Division (LD Munich) of the Unified Patent Court (UPC) caught the attention of the European patent profession by stipulating that the European Patent Office (EPO)’s problem-solution approach should be used “to the extent possible” by the UPC when assessing obviousness.Read More 23Jun2025 Has the UPC set too high burden to stop generic entry in Boehringer Ingelheim v Zentiva?The team breaks down the Lisbon Local Division’s 8 May 2025 decision in Boehringer Ingelheim v. ZentivaRead More 16Jun2025<123456…38> Type Firm News Insights PodcastsServiceProtectDealDisputeSectorHealthcare+Energy+Life SciencesChemistryMaterialsEngineeringTechCreativeArchive2026FebruaryJanuary2025DecemberNovemberOctoberSeptemberAugustJulyJuneAprilMarchFebruaryJanuary2024DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2023DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2022DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2021DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2020DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2019DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2018DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2017DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2016DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2015DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary2014DecemberNovemberOctoberAugustJulyJuneMayAprilMarchFebruaryJanuary2013DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchJanuary2012NovemberJulyJuneMayAprilFebruaryJanuary
